Biljana Djukic - Gladstone Institute of Neurological Disease

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 24 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Inhibition of CD40L with Frexalimab in Multiple Sclerosis

Patrick Vermersch,Cristina Granziera,Yang Mao-Draayer,Gary Cutter,Oleksandr Kalbus,Ivan Staikov,Michal Dufek,Stephane Saubadu,Raphael Bejuit,Philippe Truffinet,Biljana Djukic,Erik Wallstroem,Gavin Giovannoni

NEW ENGLAND JOURNAL OF MEDICINE（2024）

引用9浏览0WOS引用

Safety and Efficacy of Frexalimab in Relapsing Multiple Sclerosis: 48-Week Results from the Phase 2 Open-label Extension (S31.007)

Gavin Giovannoni,Cristina Granziera,Yang Mao-Draayer,Gary Cutter,Oleksandr Kalbus,Ivan Staikov,Michal Dufek,Stephane Saubadu,Raphael Bejuit,Biljana Djukic,Philippe Truffinet,Erik Wallstroem,Patrick Vermersch

Neurologyno. 17_supplement_1 (2024)

引用0浏览0引用

Safety and Efficacy of Frexalimab in the Treatment of Relapsing Multiple Sclerosis: 18-Month Results from the Phase 2 Open-Label Extension

Gavin Giovannoni,Cristina Granziera,Yang Mao-Draayer,Gary Cutter,Oleksandr Kalbus,Ivan Staikov,Michal Dufek,Stephane Saubadu,Raphael Bejuit, Brendan Smyth,Biljana Djukic,Philippe Truffinet,Erik Wallstroem,Patrick Vermersch

MULTIPLE SCLEROSIS JOURNALno. 3 (2024): 64-65

引用0浏览0引用

Exploratory MRI Outcomes and Plasma NfL Levels in Frexalimab-Treated Participants with Relapsing Multiple Sclerosis: Week 48 Results from the Phase 2 Open-Label Extension

Douglas L. Arnold,Jens Kuhle,Cristina Granziera,Patrick Vermersch,Biljana Djukic, Svend Geertsen, Andrea Shafer,Philippe Truffinet,Gavin Giovannoni

MULTIPLE SCLEROSIS JOURNALno. 3 (2024): 640-640

引用0浏览0引用

Exploratory Biomarker Analyses Support Frexalimab Mechanism of Action in Participants with Relapsing Multiple Sclerosis

Biljana Djukic,Roopali Gandhi, Vinh Truong,Franck Auge,Nils Ternes,Mikhail Levit, Pavithra Krishnaswami, Fabienne Schumacher, Svend Geertsen,Stephane Saubadu,Philippe Truffinet

MULTIPLE SCLEROSIS JOURNALno. 3 (2024): 327-327

引用0浏览0引用

151. Safety and Efficacy of Frexalimab in the Treatment of Relapsing Multiple Sclerosis: 18-Month Results from the Phase 2 Open-Label Extension

Multiple Sclerosis and Related Disorders (2024): 106112

引用0浏览0引用

Phase 2 Efficacy and Safety of Frexalimab: 6-Month Results of a Novel CD40L Inhibitor in Relapsing Multiple Sclerosis

MULTIPLE SCLEROSIS JOURNAL (2023): 332-333

引用0浏览0引用

Inhibition of CD40L with frexalimab blunts innate immune responses to activated T cells

Jonathan Proto,Anna Blazier,Agnes Cheong,Erin Teeple,Nima Nouri,Virginia Savova,Biljana Djukic,Dimitry Ofengeim

MULTIPLE SCLEROSIS JOURNAL (2023): 812-812

引用0浏览0引用

Dentate Gyrus and CA3 GABAergic Interneurons Bidirectionally Modulate Signatures of Internal and External Drive to CA1

Emily A. Aery Jones,Antara Rao,Misha Zilberter,Biljana Djukic,Jason S. Bant,Anna K. Gillespie,Nicole Koutsodendris,Maxine Nelson,Seo Yeon Yoon, Ky Huang,Heidi Yuan,Theodore M. Gill,Yadong Huang,Loren M. Frank

Cell Reportsno. 13 (2021): 110159-110159

引用15浏览0WOS引用

Behavioral and Neural Network Abnormalities in Human APP Transgenic Mice Resemble Those of App Knock-in Mice and Are Modulated by Familial Alzheimer's Disease Mutations but Not by Inhibition of BACE1

University of California, San Francisco,Ho Kaitlyn,Yu Gui-Qiu,Das Melanie,Sanchez Pascal E.,Djukic Biljana,Lopez Isabel,Yu Xinxing,Gill Michael,Zhang Weiping

Molecular Neurodegeneration（2020）

引用49浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn